CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability

The blows keep coming for CytoDyn. After the FDA blasted the company for pumping up their unapproved and unproven COVID-19 therapeutic, the Department of Justice and the Securities and Exchange Commission (SEC) is now subpoenaing the company and its executives.

Two investigations were disclosed in an SEC filing dated July 30. Both subpoenas seek documents and information related to CytoDyn’s public statements about leronlimab, which is being developed to treat patients with severe COVID-19.